Tests how body composition affects IVIG and SCIG treatment for CIDP
Compares intravenous and subcutaneous immune globulin in adults with CIDP.
Plain-language title generated from the registry record
Registry title: IVIG vs SCIG in CIDP
Key facts
- Where
- New Brunswick, United StatesSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT05584631, who can take part
Where in United States
- Rutgers, The State University of New Jersey Clinical Research CenterNew Brunswick, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Rutgers, The State University of New Jersey
- Trial code
- NCT05584631
- Record updated
- 11 December 2025
- Original description
Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.Read full original descriptionShow less
The Influence of Body Composition on Immunoglobulin Disposition After Intravenous and Subcutaneous Administration
Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.
Inclusion: Patients aged >18 years with a current diagnosis of CIDP (based on European Federation of Neurological sciences / Peripheral Nerve Society CIDP diagnostic criteria); 1:1 conversion of IVIG to SCIG (weekly dose conversion) must fall within 0.2-to-0.4 mg/kg dose for SCIG.
Exclusion: Patients receiving IVIG for indications other than CIDP will be excluded; Patients with liver impairment (elevations in liver enzymes of greater than 3 times the upper limit of normal) or reduced renal function (CrCl < 50 mL/min) will be excluded; Active malignancies; Diabetes; Autoimmune disease; Myasthenia gravis; Immunodeficiency.